nodes	percent_of_prediction	percent_of_DWPC	metapath
Halofantrine—CYP2C8—Montelukast—chronic obstructive pulmonary disease	0.125	0.168	CbGbCtD
Halofantrine—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.105	0.142	CbGbCtD
Halofantrine—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.105	0.142	CbGbCtD
Halofantrine—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0935	0.126	CbGbCtD
Halofantrine—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.088	0.119	CbGbCtD
Halofantrine—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0595	0.0803	CbGbCtD
Halofantrine—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0567	0.0766	CbGbCtD
Halofantrine—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0506	0.0683	CbGbCtD
Halofantrine—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0297	0.0401	CbGbCtD
Halofantrine—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.028	0.0378	CbGbCtD
Halofantrine—Rigors—Salbutamol—chronic obstructive pulmonary disease	0.00304	0.0145	CcSEcCtD
Halofantrine—CYP3A4—Lidocaine metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00269	0.0539	CbGpPWpGaD
Halofantrine—CYP3A4—Aflatoxin B1 metabolism—EPHX1—chronic obstructive pulmonary disease	0.00237	0.0476	CbGpPWpGaD
Halofantrine—Abnormal vision—Formoterol—chronic obstructive pulmonary disease	0.00229	0.0109	CcSEcCtD
Halofantrine—Abnormal vision—Arformoterol—chronic obstructive pulmonary disease	0.00229	0.0109	CcSEcCtD
Halofantrine—Pulmonary oedema—Salbutamol—chronic obstructive pulmonary disease	0.00221	0.0105	CcSEcCtD
Halofantrine—Sleep disorder—Formoterol—chronic obstructive pulmonary disease	0.0022	0.0105	CcSEcCtD
Halofantrine—Sleep disorder—Arformoterol—chronic obstructive pulmonary disease	0.0022	0.0105	CcSEcCtD
Halofantrine—Back pain—Roflumilast—chronic obstructive pulmonary disease	0.00219	0.0104	CcSEcCtD
Halofantrine—Sleep disorder—Montelukast—chronic obstructive pulmonary disease	0.00216	0.0103	CcSEcCtD
Halofantrine—Ill-defined disorder—Roflumilast—chronic obstructive pulmonary disease	0.0021	0.01	CcSEcCtD
Halofantrine—Malaise—Roflumilast—chronic obstructive pulmonary disease	0.00204	0.00974	CcSEcCtD
Halofantrine—Palpitations—Roflumilast—chronic obstructive pulmonary disease	0.002	0.00954	CcSEcCtD
Halofantrine—CYP3A4—Benzo(a)pyrene metabolism—EPHX1—chronic obstructive pulmonary disease	0.00194	0.0389	CbGpPWpGaD
Halofantrine—Myalgia—Roflumilast—chronic obstructive pulmonary disease	0.00193	0.00919	CcSEcCtD
Halofantrine—Discomfort—Roflumilast—chronic obstructive pulmonary disease	0.0019	0.00908	CcSEcCtD
Halofantrine—Stomatitis—Tiotropium—chronic obstructive pulmonary disease	0.00178	0.00847	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Roflumilast—chronic obstructive pulmonary disease	0.00168	0.00803	CcSEcCtD
Halofantrine—CYP2C8—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A2—chronic obstructive pulmonary disease	0.00165	0.0331	CbGpPWpGaD
Halofantrine—Dyspepsia—Roflumilast—chronic obstructive pulmonary disease	0.00163	0.00776	CcSEcCtD
Halofantrine—Decreased appetite—Roflumilast—chronic obstructive pulmonary disease	0.00161	0.00766	CcSEcCtD
Halofantrine—Fatigue—Roflumilast—chronic obstructive pulmonary disease	0.00159	0.0076	CcSEcCtD
Halofantrine—Constipation—Roflumilast—chronic obstructive pulmonary disease	0.00158	0.00754	CcSEcCtD
Halofantrine—Visual impairment—Tiotropium—chronic obstructive pulmonary disease	0.00158	0.00752	CcSEcCtD
Halofantrine—Abdominal distension—Salbutamol—chronic obstructive pulmonary disease	0.00157	0.00748	CcSEcCtD
Halofantrine—Arrhythmia—Aminophylline—chronic obstructive pulmonary disease	0.00155	0.00739	CcSEcCtD
Halofantrine—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—chronic obstructive pulmonary disease	0.00153	0.0307	CbGpPWpGaD
Halofantrine—Feeling abnormal—Roflumilast—chronic obstructive pulmonary disease	0.00152	0.00726	CcSEcCtD
Halofantrine—Gastrointestinal pain—Roflumilast—chronic obstructive pulmonary disease	0.00151	0.00721	CcSEcCtD
Halofantrine—CYP2C8—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A2—chronic obstructive pulmonary disease	0.0015	0.0301	CbGpPWpGaD
Halofantrine—Urticaria—Roflumilast—chronic obstructive pulmonary disease	0.00147	0.007	CcSEcCtD
Halofantrine—Arrhythmia—Tiotropium—chronic obstructive pulmonary disease	0.00146	0.00697	CcSEcCtD
Halofantrine—Abdominal pain—Roflumilast—chronic obstructive pulmonary disease	0.00146	0.00697	CcSEcCtD
Halofantrine—Back pain—Tiotropium—chronic obstructive pulmonary disease	0.00138	0.00657	CcSEcCtD
Halofantrine—Stomatitis—Salbutamol—chronic obstructive pulmonary disease	0.00135	0.00645	CcSEcCtD
Halofantrine—Palpitations—Aminophylline—chronic obstructive pulmonary disease	0.00133	0.00636	CcSEcCtD
Halofantrine—Asthenia—Roflumilast—chronic obstructive pulmonary disease	0.00133	0.00632	CcSEcCtD
Halofantrine—Convulsion—Aminophylline—chronic obstructive pulmonary disease	0.00131	0.00624	CcSEcCtD
Halofantrine—Visual impairment—Arformoterol—chronic obstructive pulmonary disease	0.00127	0.00607	CcSEcCtD
Halofantrine—Visual impairment—Formoterol—chronic obstructive pulmonary disease	0.00127	0.00607	CcSEcCtD
Halofantrine—Pulmonary oedema—Prednisolone—chronic obstructive pulmonary disease	0.00127	0.00604	CcSEcCtD
Halofantrine—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.00126	0.00603	CcSEcCtD
Halofantrine—Palpitations—Tiotropium—chronic obstructive pulmonary disease	0.00126	0.006	CcSEcCtD
Halofantrine—Cough—Tiotropium—chronic obstructive pulmonary disease	0.00124	0.00593	CcSEcCtD
Halofantrine—Anaphylactic shock—Aminophylline—chronic obstructive pulmonary disease	0.00123	0.00588	CcSEcCtD
Halofantrine—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.00122	0.00583	CcSEcCtD
Halofantrine—Chest pain—Tiotropium—chronic obstructive pulmonary disease	0.00121	0.00578	CcSEcCtD
Halofantrine—Myalgia—Tiotropium—chronic obstructive pulmonary disease	0.00121	0.00578	CcSEcCtD
Halofantrine—Arthralgia—Tiotropium—chronic obstructive pulmonary disease	0.00121	0.00578	CcSEcCtD
Halofantrine—CYP2C8—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—chronic obstructive pulmonary disease	0.0012	0.0241	CbGpPWpGaD
Halofantrine—Arrhythmia—Arformoterol—chronic obstructive pulmonary disease	0.00118	0.00562	CcSEcCtD
Halofantrine—Arrhythmia—Formoterol—chronic obstructive pulmonary disease	0.00118	0.00562	CcSEcCtD
Halofantrine—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.00117	0.0056	CcSEcCtD
Halofantrine—Anorexia—Aminophylline—chronic obstructive pulmonary disease	0.00117	0.0056	CcSEcCtD
Halofantrine—Rash—Roflumilast—chronic obstructive pulmonary disease	0.00116	0.00556	CcSEcCtD
Halofantrine—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.00116	0.00555	CcSEcCtD
Halofantrine—Tinnitus—Salbutamol—chronic obstructive pulmonary disease	0.00116	0.00554	CcSEcCtD
Halofantrine—Headache—Roflumilast—chronic obstructive pulmonary disease	0.00116	0.00552	CcSEcCtD
Halofantrine—Chills—Salbutamol—chronic obstructive pulmonary disease	0.00112	0.00533	CcSEcCtD
Halofantrine—Arrhythmia—Salbutamol—chronic obstructive pulmonary disease	0.00111	0.00531	CcSEcCtD
Halofantrine—Back pain—Arformoterol—chronic obstructive pulmonary disease	0.00111	0.0053	CcSEcCtD
Halofantrine—Back pain—Formoterol—chronic obstructive pulmonary disease	0.00111	0.0053	CcSEcCtD
Halofantrine—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.0011	0.00523	CcSEcCtD
Halofantrine—CYP2C8—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—chronic obstructive pulmonary disease	0.00109	0.0219	CbGpPWpGaD
Halofantrine—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.00108	0.00517	CcSEcCtD
Halofantrine—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.00107	0.00511	CcSEcCtD
Halofantrine—Ill-defined disorder—Arformoterol—chronic obstructive pulmonary disease	0.00107	0.00508	CcSEcCtD
Halofantrine—Ill-defined disorder—Formoterol—chronic obstructive pulmonary disease	0.00107	0.00508	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.00106	0.00505	CcSEcCtD
Halofantrine—Back pain—Salbutamol—chronic obstructive pulmonary disease	0.00105	0.00501	CcSEcCtD
Halofantrine—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.00104	0.00498	CcSEcCtD
Halofantrine—Malaise—Arformoterol—chronic obstructive pulmonary disease	0.00104	0.00494	CcSEcCtD
Halofantrine—Malaise—Formoterol—chronic obstructive pulmonary disease	0.00104	0.00494	CcSEcCtD
Halofantrine—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.00102	0.00488	CcSEcCtD
Halofantrine—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.00102	0.00484	CcSEcCtD
Halofantrine—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.00102	0.00484	CcSEcCtD
Halofantrine—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.00101	0.00481	CcSEcCtD
Halofantrine—Ill-defined disorder—Salbutamol—chronic obstructive pulmonary disease	0.00101	0.0048	CcSEcCtD
Halofantrine—Cough—Formoterol—chronic obstructive pulmonary disease	0.001	0.00478	CcSEcCtD
Halofantrine—Cough—Arformoterol—chronic obstructive pulmonary disease	0.001	0.00478	CcSEcCtD
Halofantrine—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.000994	0.00474	CcSEcCtD
Halofantrine—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000994	0.00474	CcSEcCtD
Halofantrine—CYP3A4—Aflatoxin B1 metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000986	0.0198	CbGpPWpGaD
Halofantrine—Cough—Montelukast—chronic obstructive pulmonary disease	0.000982	0.00468	CcSEcCtD
Halofantrine—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000979	0.00467	CcSEcCtD
Halofantrine—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.000978	0.00467	CcSEcCtD
Halofantrine—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.000978	0.00467	CcSEcCtD
Halofantrine—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.000978	0.00467	CcSEcCtD
Halofantrine—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.000978	0.00467	CcSEcCtD
Halofantrine—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.000978	0.00467	CcSEcCtD
Halofantrine—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.000978	0.00467	CcSEcCtD
Halofantrine—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.000978	0.00467	CcSEcCtD
Halofantrine—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.000975	0.00465	CcSEcCtD
Halofantrine—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000974	0.00465	CcSEcCtD
Halofantrine—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.000966	0.00461	CcSEcCtD
Halofantrine—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000966	0.00461	CcSEcCtD
Halofantrine—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000959	0.00457	CcSEcCtD
Halofantrine—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000958	0.00457	CcSEcCtD
Halofantrine—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000958	0.00457	CcSEcCtD
Halofantrine—CYP3A5—Aflatoxin activation and detoxification—CYP1A2—chronic obstructive pulmonary disease	0.000954	0.0191	CbGpPWpGaD
Halofantrine—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.00095	0.00453	CcSEcCtD
Halofantrine—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000947	0.00452	CcSEcCtD
Halofantrine—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000938	0.00447	CcSEcCtD
Halofantrine—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000938	0.00447	CcSEcCtD
Halofantrine—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000924	0.00441	CcSEcCtD
Halofantrine—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000924	0.00441	CcSEcCtD
Halofantrine—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000924	0.00441	CcSEcCtD
Halofantrine—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000923	0.0044	CcSEcCtD
Halofantrine—Pulmonary oedema—Prednisone—chronic obstructive pulmonary disease	0.000921	0.00439	CcSEcCtD
Halofantrine—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000918	0.00438	CcSEcCtD
Halofantrine—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000918	0.00438	CcSEcCtD
Halofantrine—CYP3A5—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000916	0.0184	CbGpPWpGaD
Halofantrine—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000912	0.00435	CcSEcCtD
Halofantrine—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.000899	0.00429	CcSEcCtD
Halofantrine—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000885	0.00422	CcSEcCtD
Halofantrine—CYP3A5—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000881	0.0177	CbGpPWpGaD
Halofantrine—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000872	0.00416	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000854	0.00407	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000854	0.00407	CcSEcCtD
Halofantrine—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000844	0.00403	CcSEcCtD
Halofantrine—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000843	0.00402	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000837	0.00399	CcSEcCtD
Halofantrine—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000825	0.00394	CcSEcCtD
Halofantrine—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000825	0.00394	CcSEcCtD
Halofantrine—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000825	0.00393	CcSEcCtD
Halofantrine—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000822	0.00392	CcSEcCtD
Halofantrine—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000815	0.00389	CcSEcCtD
Halofantrine—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000808	0.00386	CcSEcCtD
Halofantrine—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000808	0.00386	CcSEcCtD
Halofantrine—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000808	0.00386	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000807	0.00385	CcSEcCtD
Halofantrine—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000802	0.00382	CcSEcCtD
Halofantrine—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000802	0.00382	CcSEcCtD
Halofantrine—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000795	0.00379	CcSEcCtD
Halofantrine—CYP2C8—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000793	0.0159	CbGpPWpGaD
Halofantrine—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000792	0.00378	CcSEcCtD
Halofantrine—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000783	0.00374	CcSEcCtD
Halofantrine—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000779	0.00372	CcSEcCtD
Halofantrine—CYP2D6—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.000778	0.0156	CbGpPWpGaD
Halofantrine—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000777	0.00371	CcSEcCtD
Halofantrine—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000776	0.0037	CcSEcCtD
Halofantrine—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000773	0.00369	CcSEcCtD
Halofantrine—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000773	0.00369	CcSEcCtD
Halofantrine—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000772	0.00368	CcSEcCtD
Halofantrine—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.00077	0.00367	CcSEcCtD
Halofantrine—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000768	0.00366	CcSEcCtD
Halofantrine—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000767	0.00366	CcSEcCtD
Halofantrine—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000767	0.00366	CcSEcCtD
Halofantrine—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000763	0.00364	CcSEcCtD
Halofantrine—CYP2C8—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000763	0.0153	CbGpPWpGaD
Halofantrine—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000757	0.00361	CcSEcCtD
Halofantrine—CYP3A4—Aflatoxin B1 metabolism—GSTM1—chronic obstructive pulmonary disease	0.000756	0.0152	CbGpPWpGaD
Halofantrine—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000751	0.00358	CcSEcCtD
Halofantrine—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000745	0.00355	CcSEcCtD
Halofantrine—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000745	0.00355	CcSEcCtD
Halofantrine—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000741	0.00354	CcSEcCtD
Halofantrine—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000741	0.00354	CcSEcCtD
Halofantrine—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000739	0.00352	CcSEcCtD
Halofantrine—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000733	0.00349	CcSEcCtD
Halofantrine—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000732	0.00349	CcSEcCtD
Halofantrine—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000732	0.00349	CcSEcCtD
Halofantrine—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.00073	0.00348	CcSEcCtD
Halofantrine—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.00073	0.00348	CcSEcCtD
Halofantrine—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000728	0.00347	CcSEcCtD
Halofantrine—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000726	0.00346	CcSEcCtD
Halofantrine—Face oedema—Prednisone—chronic obstructive pulmonary disease	0.000725	0.00346	CcSEcCtD
Halofantrine—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000724	0.00345	CcSEcCtD
Halofantrine—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000703	0.00336	CcSEcCtD
Halofantrine—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.0007	0.00334	CcSEcCtD
Halofantrine—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.00069	0.00329	CcSEcCtD
Halofantrine—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.000689	0.00329	CcSEcCtD
Halofantrine—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000673	0.00321	CcSEcCtD
Halofantrine—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000673	0.00321	CcSEcCtD
Halofantrine—CYP3A5—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000665	0.0133	CbGpPWpGaD
Halofantrine—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000663	0.00316	CcSEcCtD
Halofantrine—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000663	0.00316	CcSEcCtD
Halofantrine—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000659	0.00314	CcSEcCtD
Halofantrine—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	0.000653	0.00312	CcSEcCtD
Halofantrine—CYP2D6—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000651	0.0131	CbGpPWpGaD
Halofantrine—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.00065	0.0031	CcSEcCtD
Halofantrine—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000642	0.00306	CcSEcCtD
Halofantrine—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000642	0.00306	CcSEcCtD
Halofantrine—CYP3A5—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00064	0.0128	CbGpPWpGaD
Halofantrine—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000639	0.00305	CcSEcCtD
Halofantrine—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000635	0.00303	CcSEcCtD
Halofantrine—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000628	0.003	CcSEcCtD
Halofantrine—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000626	0.00299	CcSEcCtD
Halofantrine—CYP2D6—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000626	0.0126	CbGpPWpGaD
Halofantrine—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.00062	0.00296	CcSEcCtD
Halofantrine—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.00062	0.00296	CcSEcCtD
Halofantrine—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000607	0.0029	CcSEcCtD
Halofantrine—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000606	0.00289	CcSEcCtD
Halofantrine—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000596	0.00284	CcSEcCtD
Halofantrine—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000596	0.00284	CcSEcCtD
Halofantrine—Rash—Formoterol—chronic obstructive pulmonary disease	0.000591	0.00282	CcSEcCtD
Halofantrine—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000591	0.00282	CcSEcCtD
Halofantrine—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000591	0.00282	CcSEcCtD
Halofantrine—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000591	0.00282	CcSEcCtD
Halofantrine—Headache—Formoterol—chronic obstructive pulmonary disease	0.000587	0.0028	CcSEcCtD
Halofantrine—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000587	0.0028	CcSEcCtD
Halofantrine—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000586	0.0117	CbGpPWpGaD
Halofantrine—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000585	0.00279	CcSEcCtD
Halofantrine—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000584	0.00279	CcSEcCtD
Halofantrine—Rash—Montelukast—chronic obstructive pulmonary disease	0.000579	0.00276	CcSEcCtD
Halofantrine—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000579	0.00276	CcSEcCtD
Halofantrine—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000577	0.00275	CcSEcCtD
Halofantrine—CYP2C8—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000576	0.0116	CbGpPWpGaD
Halofantrine—Headache—Montelukast—chronic obstructive pulmonary disease	0.000575	0.00274	CcSEcCtD
Halofantrine—CYP2D6—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000565	0.0113	CbGpPWpGaD
Halofantrine—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000563	0.00269	CcSEcCtD
Halofantrine—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000561	0.00268	CcSEcCtD
Halofantrine—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000558	0.00266	CcSEcCtD
Halofantrine—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000558	0.00266	CcSEcCtD
Halofantrine—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000557	0.00266	CcSEcCtD
Halofantrine—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000557	0.00266	CcSEcCtD
Halofantrine—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000555	0.00265	CcSEcCtD
Halofantrine—CYP2C8—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000554	0.0111	CbGpPWpGaD
Halofantrine—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000546	0.0026	CcSEcCtD
Halofantrine—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000539	0.00257	CcSEcCtD
Halofantrine—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000526	0.00251	CcSEcCtD
Halofantrine—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000523	0.0025	CcSEcCtD
Halofantrine—CYP3A4—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.000509	0.0102	CbGpPWpGaD
Halofantrine—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000508	0.00242	CcSEcCtD
Halofantrine—CYP2D6—Melatonin metabolism and effects—CYP1A2—chronic obstructive pulmonary disease	0.000484	0.0097	CbGpPWpGaD
Halofantrine—KCNH2—SIDS Susceptibility Pathways—IL13—chronic obstructive pulmonary disease	0.00048	0.00963	CbGpPWpGaD
Halofantrine—CYP2D6—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000473	0.00949	CbGpPWpGaD
Halofantrine—KCNH2—Hematopoietic Stem Cell Differentiation—IL1B—chronic obstructive pulmonary disease	0.000468	0.00938	CbGpPWpGaD
Halofantrine—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.000464	0.00221	CcSEcCtD
Halofantrine—CYP3A4—Estrogen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000463	0.00929	CbGpPWpGaD
Halofantrine—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000456	0.00218	CcSEcCtD
Halofantrine—CYP2D6—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000455	0.00912	CbGpPWpGaD
Halofantrine—KCNH2—Neuronal System—CHRNA5—chronic obstructive pulmonary disease	0.000449	0.00901	CbGpPWpGaD
Halofantrine—CYP3A4—Aflatoxin activation and detoxification—CYP1A2—chronic obstructive pulmonary disease	0.000443	0.00889	CbGpPWpGaD
Halofantrine—KCNH2—SIDS Susceptibility Pathways—SLC6A4—chronic obstructive pulmonary disease	0.000433	0.00869	CbGpPWpGaD
Halofantrine—CYP3A4—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000426	0.00854	CbGpPWpGaD
Halofantrine—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.00042	0.002	CcSEcCtD
Halofantrine—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000418	0.002	CcSEcCtD
Halofantrine—CYP3A4—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000409	0.00821	CbGpPWpGaD
Halofantrine—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000408	0.00194	CcSEcCtD
Halofantrine—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000403	0.00192	CcSEcCtD
Halofantrine—Convulsion—Prednisone—chronic obstructive pulmonary disease	0.000392	0.00187	CcSEcCtD
Halofantrine—CYP3A5—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000389	0.0078	CbGpPWpGaD
Halofantrine—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000385	0.00184	CcSEcCtD
Halofantrine—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000385	0.00184	CcSEcCtD
Halofantrine—CYP2C8—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000381	0.00764	CbGpPWpGaD
Halofantrine—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.00038	0.00181	CcSEcCtD
Halofantrine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.00038	0.00762	CbGpPWpGaD
Halofantrine—CYP3A5—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000375	0.00752	CbGpPWpGaD
Halofantrine—CYP2D6—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.000375	0.00752	CbGpPWpGaD
Halofantrine—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.00037	0.00741	CbGpPWpGaD
Halofantrine—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.000369	0.00176	CcSEcCtD
Halofantrine—KCNH2—Neuronal System—CHRNA3—chronic obstructive pulmonary disease	0.000366	0.00734	CbGpPWpGaD
Halofantrine—CYP3A4—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.000355	0.00712	CbGpPWpGaD
Halofantrine—Anorexia—Prednisone—chronic obstructive pulmonary disease	0.000352	0.00168	CcSEcCtD
Halofantrine—CYP2D6—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.000351	0.00705	CbGpPWpGaD
Halofantrine—CYP2C8—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000337	0.00675	CbGpPWpGaD
Halofantrine—CYP3A4—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000336	0.00675	CbGpPWpGaD
Halofantrine—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000336	0.0016	CcSEcCtD
Halofantrine—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000336	0.0016	CcSEcCtD
Halofantrine—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	0.000331	0.00158	CcSEcCtD
Halofantrine—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000329	0.0066	CbGpPWpGaD
Halofantrine—CYP2C8—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000325	0.00652	CbGpPWpGaD
Halofantrine—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000325	0.00155	CcSEcCtD
Halofantrine—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000321	0.00153	CcSEcCtD
Halofantrine—Rash—Prednisolone—chronic obstructive pulmonary disease	0.00032	0.00153	CcSEcCtD
Halofantrine—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.00032	0.00153	CcSEcCtD
Halofantrine—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000318	0.00152	CcSEcCtD
Halofantrine—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000318	0.00152	CcSEcCtD
Halofantrine—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000316	0.00151	CcSEcCtD
Halofantrine—CYP3A4—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000309	0.0062	CbGpPWpGaD
Halofantrine—CYP3A5—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000308	0.00618	CbGpPWpGaD
Halofantrine—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000304	0.00145	CcSEcCtD
Halofantrine—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000302	0.00144	CcSEcCtD
Halofantrine—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000302	0.00144	CcSEcCtD
Halofantrine—KCNH2—SIDS Susceptibility Pathways—IL10—chronic obstructive pulmonary disease	0.0003	0.00602	CbGpPWpGaD
Halofantrine—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000297	0.00596	CbGpPWpGaD
Halofantrine—Urticaria—Prednisone—chronic obstructive pulmonary disease	0.000293	0.0014	CcSEcCtD
Halofantrine—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000292	0.00139	CcSEcCtD
Halofantrine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000278	0.00558	CbGpPWpGaD
Halofantrine—CYP2C8—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000277	0.00555	CbGpPWpGaD
Halofantrine—CYP2D6—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000276	0.00555	CbGpPWpGaD
Halofantrine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000276	0.00554	CbGpPWpGaD
Halofantrine—KCNH2—Hematopoietic Stem Cell Differentiation—IL6—chronic obstructive pulmonary disease	0.000274	0.00549	CbGpPWpGaD
Halofantrine—CYP3A5—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000273	0.00547	CbGpPWpGaD
Halofantrine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.00027	0.00542	CbGpPWpGaD
Halofantrine—CYP2C8—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000267	0.00535	CbGpPWpGaD
Halofantrine—CYP2D6—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000267	0.00535	CbGpPWpGaD
Halofantrine—KCNH2—SIDS Susceptibility Pathways—HTR2A—chronic obstructive pulmonary disease	0.000266	0.00533	CbGpPWpGaD
Halofantrine—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000265	0.00126	CcSEcCtD
Halofantrine—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000261	0.00125	CcSEcCtD
Halofantrine—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000252	0.0012	CcSEcCtD
Halofantrine—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000244	0.00116	CcSEcCtD
Halofantrine—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000239	0.0048	CbGpPWpGaD
Halofantrine—CYP2C8—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000236	0.00474	CbGpPWpGaD
Halofantrine—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000235	0.00112	CcSEcCtD
Halofantrine—Rash—Prednisone—chronic obstructive pulmonary disease	0.000233	0.00111	CcSEcCtD
Halofantrine—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000232	0.00111	CcSEcCtD
Halofantrine—Headache—Prednisone—chronic obstructive pulmonary disease	0.000231	0.0011	CcSEcCtD
Halofantrine—CYP3A5—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000224	0.00449	CbGpPWpGaD
Halofantrine—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000219	0.00105	CcSEcCtD
Halofantrine—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000219	0.0044	CbGpPWpGaD
Halofantrine—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000219	0.00438	CbGpPWpGaD
Halofantrine—CYP3A5—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000197	0.00395	CbGpPWpGaD
Halofantrine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000196	0.00394	CbGpPWpGaD
Halofantrine—CYP3A5—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000195	0.00391	CbGpPWpGaD
Halofantrine—CYP2C8—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000194	0.00389	CbGpPWpGaD
Halofantrine—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000194	0.00389	CbGpPWpGaD
Halofantrine—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000181	0.00363	CbGpPWpGaD
Halofantrine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000177	0.00354	CbGpPWpGaD
Halofantrine—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000174	0.0035	CbGpPWpGaD
Halofantrine—CYP2C8—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000171	0.00342	CbGpPWpGaD
Halofantrine—CYP2C8—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000169	0.00338	CbGpPWpGaD
Halofantrine—KCNH2—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	0.000164	0.00329	CbGpPWpGaD
Halofantrine—CYP3A5—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000164	0.00328	CbGpPWpGaD
Halofantrine—CYP3A5—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000161	0.00324	CbGpPWpGaD
Halofantrine—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000159	0.00319	CbGpPWpGaD
Halofantrine—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000159	0.00319	CbGpPWpGaD
Halofantrine—KCNH2—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	0.000157	0.00316	CbGpPWpGaD
Halofantrine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000143	0.00287	CbGpPWpGaD
Halofantrine—CYP2C8—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000142	0.00284	CbGpPWpGaD
Halofantrine—CYP2D6—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.00014	0.00281	CbGpPWpGaD
Halofantrine—CYP2C8—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.00014	0.0028	CbGpPWpGaD
Halofantrine—CYP2D6—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000138	0.00278	CbGpPWpGaD
Halofantrine—CYP3A5—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000137	0.00274	CbGpPWpGaD
Halofantrine—CYP3A5—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.000135	0.0027	CbGpPWpGaD
Halofantrine—KCNH2—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	0.000133	0.00267	CbGpPWpGaD
Halofantrine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000128	0.00258	CbGpPWpGaD
Halofantrine—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000127	0.00254	CbGpPWpGaD
Halofantrine—CYP3A5—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000125	0.00252	CbGpPWpGaD
Halofantrine—CYP3A5—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	0.000124	0.00248	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	0.00012	0.00241	CbGpPWpGaD
Halofantrine—CYP3A5—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000119	0.00239	CbGpPWpGaD
Halofantrine—CYP2C8—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000118	0.00237	CbGpPWpGaD
Halofantrine—CYP3A5—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	0.000117	0.00235	CbGpPWpGaD
Halofantrine—CYP2C8—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.000117	0.00234	CbGpPWpGaD
Halofantrine—CYP2D6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000116	0.00233	CbGpPWpGaD
Halofantrine—CYP2D6—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000115	0.0023	CbGpPWpGaD
Halofantrine—KCNH2—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	0.000114	0.00229	CbGpPWpGaD
Halofantrine—CYP2C8—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000109	0.00218	CbGpPWpGaD
Halofantrine—CYP2C8—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	0.000107	0.00215	CbGpPWpGaD
Halofantrine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000104	0.00209	CbGpPWpGaD
Halofantrine—CYP2C8—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000103	0.00207	CbGpPWpGaD
Halofantrine—CYP2C8—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	0.000102	0.00204	CbGpPWpGaD
Halofantrine—CYP2D6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	9.71e-05	0.00195	CbGpPWpGaD
Halofantrine—CYP2D6—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	9.58e-05	0.00192	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—APIP—chronic obstructive pulmonary disease	9.57e-05	0.00192	CbGpPWpGaD
Halofantrine—KCNH2—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	9.22e-05	0.00185	CbGpPWpGaD
Halofantrine—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	9.16e-05	0.00184	CbGpPWpGaD
Halofantrine—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	9.05e-05	0.00182	CbGpPWpGaD
Halofantrine—CYP2D6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	8.92e-05	0.00179	CbGpPWpGaD
Halofantrine—CYP2D6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	8.8e-05	0.00176	CbGpPWpGaD
Halofantrine—CYP2D6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	8.46e-05	0.0017	CbGpPWpGaD
Halofantrine—CYP2D6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	8.34e-05	0.00167	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—APIP—chronic obstructive pulmonary disease	8.29e-05	0.00166	CbGpPWpGaD
Halofantrine—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	7.61e-05	0.00153	CbGpPWpGaD
Halofantrine—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	7.51e-05	0.00151	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	6.8e-05	0.00136	CbGpPWpGaD
Halofantrine—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	6.35e-05	0.00127	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	6.34e-05	0.00127	CbGpPWpGaD
Halofantrine—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	6.26e-05	0.00126	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—GC—chronic obstructive pulmonary disease	6.17e-05	0.00124	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	5.91e-05	0.00119	CbGpPWpGaD
Halofantrine—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	5.83e-05	0.00117	CbGpPWpGaD
Halofantrine—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	5.75e-05	0.00115	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	5.73e-05	0.00115	CbGpPWpGaD
Halofantrine—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	5.53e-05	0.00111	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	5.49e-05	0.0011	CbGpPWpGaD
Halofantrine—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	5.45e-05	0.00109	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	5.45e-05	0.00109	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—GC—chronic obstructive pulmonary disease	5.34e-05	0.00107	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	4.97e-05	0.000996	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	4.51e-05	0.000904	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	4.45e-05	0.000892	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	4.38e-05	0.000879	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	4.08e-05	0.000818	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	3.96e-05	0.000793	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.37e-05	0.000676	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—GCLC—chronic obstructive pulmonary disease	3.33e-05	0.000668	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—CTGF—chronic obstructive pulmonary disease	3.04e-05	0.000609	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.95e-05	0.000591	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.92e-05	0.000585	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—GCLC—chronic obstructive pulmonary disease	2.88e-05	0.000578	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	2.87e-05	0.000575	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.8e-05	0.000561	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	2.69e-05	0.000539	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.67e-05	0.000535	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—CTGF—chronic obstructive pulmonary disease	2.63e-05	0.000528	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.42e-05	0.000486	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.4e-05	0.00048	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	2.37e-05	0.000475	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.34e-05	0.000468	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.3e-05	0.000462	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	2.16e-05	0.000433	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.15e-05	0.00043	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.03e-05	0.000408	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.02e-05	0.000406	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.99e-05	0.0004	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.99e-05	0.000399	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.86e-05	0.000373	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.76e-05	0.000353	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.66e-05	0.000333	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.64e-05	0.000328	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.57e-05	0.000314	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	1.55e-05	0.00031	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.53e-05	0.000306	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.45e-05	0.00029	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	1.41e-05	0.000283	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—ALB—chronic obstructive pulmonary disease	1.38e-05	0.000277	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—NOS3—chronic obstructive pulmonary disease	1.32e-05	0.000265	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.3e-05	0.000261	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—ALB—chronic obstructive pulmonary disease	1.2e-05	0.00024	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—NOS3—chronic obstructive pulmonary disease	1.15e-05	0.00023	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.09e-05	0.000218	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.07e-05	0.000215	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	9.98e-06	0.0002	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	9.83e-06	0.000197	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	9.46e-06	0.00019	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	9.41e-06	0.000189	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	6.43e-06	0.000129	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	6.15e-06	0.000123	CbGpPWpGaD
